The roles of transforming growth factor type beta3 (TGF-beta3) and mast cells in the pathogenesis of scleroderma.
Scleroderma is a connective tissue disorder characterised by excessive accumulation of collagen in the skin and internal organs. The most likely explanation for this process is local activation of collagen synthesis from fibroblasts. Our intention was to elucidate whether TGF-beta3 and mast cells play a pathogenic role in abnormal connective tissue formation in scleroderma. In this study, skin biopsies from 20 patients with scleroderma and five from healthy individuals were studied by an indirect immunoperoxidase technique to determine the immunoreactivity of TGF-beta3 in the dermis. In addition, skin samples were stained with toluidine blue to count the number of mast cells in scleroderma, and tissues were examined under the electron microscope to evaluate the ultrastructural changes. Increased TGF-beta3 immunoreactivities were detected in the dermis in the patient's skin, suggesting the presence of a subpopulation responsible for the increased collagen production. Mast cell counts in the skin of patients with scleroderma were significantly greater (19.2 +/- 4.1/unit) than those of normal controls (4.4 +/- 1.2/unit). Ultrastructural observations indicated that there is a close relationship between the mast cells and fibroblasts. These results suggest that fibrosis in scleroderma could evolve through the activation of fibroblasts and the regulatory mechanisms that appear to modulate the behavior of these cells with respect to collagen production.
D000328:Adult; D015415:Biomarkers / Q000032:analysis; D001707:Biopsy, Needle; D016022:Case-Control Studies; D002465:Cell Movement; D005260:Female; D005347:Fibroblasts / Q000502:physiology; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008407:Mast Cells / Q000473:pathology / Q000502:physiology*; D008854:Microscopy, Electron; D008875:Middle Aged; D010784:Photomicrography; D011379:Prognosis; D012016:Reference Values; D012594:Scleroderma, Localized / Q000473:pathology* / Q000503:physiopathology*; D012680:Sensitivity and Specificity; D012867:Skin / Q000473:pathology / Q000648:ultrastructure; D016212:Transforming Growth Factor beta / Q000032:analysis / Q000378:metabolism*; D053782:Transforming Growth Factor beta3
D015415:Biomarkers; D016212:Transforming Growth Factor beta; D053782:Transforming Growth Factor beta3